Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]